{"id":810,"date":"2021-02-05T06:00:01","date_gmt":"2021-02-05T06:00:01","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=810"},"modified":"2021-02-05T06:00:01","modified_gmt":"2021-02-05T06:00:01","slug":"01-feb-2021-tocilizumab-associated-with-reduced-mortality-and-faster-clinical-improvement-in-patients-with-higher-il-6","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/01-feb-2021-tocilizumab-associated-with-reduced-mortality-and-faster-clinical-improvement-in-patients-with-higher-il-6\/","title":{"rendered":"(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.28.21249932v1<\/p>\n<div id=\"sec-3\" class=\"subsection\">\n<p id=\"p-12\" class=\"\">Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions. The reduced death rate was demonstrated in patients treated with TCZ and baseline IL-6 &gt;100 pg\/ml (hazard ratio [HR]: 0.27, 95% confidence interval [CI]:0.10-0.78), or those needing oxygen supplementations who worsened within 7 days of hospitalization (HR: 0.38, 95% CI:0.16-0.88). The best effectiveness of TCZ was achieved in patients with a combination of baseline IL-6&gt;100 pg\/ml and either SpO2\u226490% (HR for death, mechanical ventilation, and clinical improvement after 21 or 28 days: 0.07, 0.14, 5.53, 5.18 respectively) or requiring oxygen supplementation (HR for death and clinical improvement after 21 or 28 days, 0.18, 2.66, 2.85 respectively). Tocilizumab administered for COVID-19 in patients with a baseline concentration of IL-6&gt;100 pg\/ml is associated with reduced mortality and faster clinical improvement, particularly if there is a need for oxygen supplementation due to SpO2\u226490%.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis https:\/\/www.medrxiv.org\/content\/10.1101\/2021.01.28.21249932v1 Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions.&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/01-feb-2021-tocilizumab-associated-with-reduced-mortality-and-faster-clinical-improvement-in-patients-with-higher-il-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/810"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=810"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/810\/revisions"}],"predecessor-version":[{"id":811,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/810\/revisions\/811"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}